کارگاه های آموزشی مرکز اطلاعات علمی جهاد دانشگاهی

کارگاه آنلاین
کاربرد نرم افزار SPSS در پژوهش

کارگاه آنلاین
اصول تنظیم قراردادها

کارگاه آنلاین
پروپوزال نویسی
Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China

Weilan WANG, *Man ZHU, Daihong GUO, Chao CHEN, Dongxiao WANG, Fei PEI, Liang MA

Dept. of Pharmaceutical Care, Chinese PLA General Hospital, Beijing, China

*Corresponding Author: Tel: +86-10-66937243 Email: wangweilan50@sohu.com

(Received 12 Nov 2012; accepted 05 Feb 2013)

Abstract
Background: To evaluate off-label and off-NCCN guidelines uses of antineoplastic drugs in a major Chinese hospital.
Methods: Totally 1122 patients were selected from July to December 2011. Then, the off-label and off-NCCN guidelines uses of antineoplastic drugs were analyzed.
Results: In 798 of 1122 patients (71.12%), drugs were used for off-label. In 317 of 1122 patients (28.25%), the drugs were prescribed for off-label and off-NCCN guidelines. 2591 medical orders for 1122 patients, 1051/2591 (40.56%) medical orders were off-label; 445/2591 (17.17%) medical orders were off-label and off-NCCN guidelines. In 445 off-label and off-NCCN medical orders, 399 (89.66%) were unapproved indications, 38 (8.54%) were unapproved drug concentration and 12 (2.70%) were unapproved route of administration. Percentage of off-label and off-NCCN guidelines drug uses in male was higher than that in female (21.92% vs. 11.39%, P<0.01). Compared with other lines of treatment, percentage of off-label and off-NCCN guidelines drug uses in postoperative adjuvant was the smallest (P<0.01) and percentage in three or multi-line treatments was the highest (P<0.01). The pancreatic cancer possessed the highest percentage (38.74%) of off-label and off-NCCN guidelines drug uses among all types of cancer (P<0.01).
Conclusion: Off-label uses of antineoplastic drugs are generally common in China hospitals based on NCCN guidelines. The fact suggests that anti-tumor treatment was relatively standard in China. Off-label and off-NCCN guidelines drug uses were mainly for individual treatment. Doctors should fully consider the adverse drug reaction, contraindication, cautions and increase the drug security monitoring. Uncorrected drug concentration should be avoided for drug risk.

Keywords: Antineoplastic drug use, Off-label and off-NCCN guidelines, China

Introduction

Any new drug labeled for an indication, dose and route of administration by drug approval authorities is on-label. Use of a drug outside the terms of its official labeling is referred to as off-label (1). Off-label prescription is common in medical practice, especially in oncology where drugs are often prescribed off-label (2-7). It is mainly because effective approved drugs are scarce. In addition, many widespread anticancer drugs have not gained the label for all the indications under which they can be effectively employed. The pressure from patients, who require in any case treatment for their disease, is another main reason for off-label prescriptions in China. Last but not least, the rapid diffusion of preliminary results of clinical trials and the lagged approval of new drugs (or extension of indications of drugs already approved) by the European Medicines Agency and the US Food and Drug Administration (FDA) are another potential important reasons for off-label...
prescriptions (8,9). Antineoplastic drugs could lead to possible health, legal and economic problems without instruction supports due to the potential high toxic effects, narrow safety scope and high price. However, few data are available on the incidence of off-label use of antineoplastic drugs (4, 10). In 2004, Susan and Michael assessed that 22% of the prescriptions were either off-label or unlicensed at Peter MacCallum Cancer Centre, Australia (6). A recent estimation by the National Comprehensive Cancer Network (NCCN) calculated that 50-75% uses of all drugs in cancer care in the United State were off-label (11). A large study conducted in the USA revealed that 33.2% of chemotherapy was off-label (12). An Australia survey assessed that a total of 448 protocols contained 82 different drugs across 15 tumor groups. Overall, 189 (42.2%) of protocols were off-label, and three (0.7%) were unlicensed (13). An Italian prospective, observational, multicenter survey revealed that off-label use of antineoplastic drugs represented less than 20% of the prescriptions and most of them were based on scientific evidences of efficacy (14).

In China, leaflet is the legal document to deal with medical dispute and there is no clear legislation for drug uses beyond labels. NCCN guidelines sponsored and formulated by the 21 top American cancer centers were widely recognized by global community of tumor circles. The NCCN guidelines document is evidence-based and consensus-driven, ensuring that all patients receive preventive, diagnostic treatment and supportive services for the optimal outcomes. Currently, the NCCN guidelines document has been the first-hand reference material for cancer treatment since its introduction to China in 2005. There was only one research involving antineoplastic drug uses based on the specifications and NCCN guidelines. The survey on prescribing practices of 10 important drugs used for cancer was conducted in March 2010 in India, in which off-label use was further evaluated by NCCN guidelines (15). To date, there was no relevant research data about antineoplastic drug uses according to the specifications or/and NCCN guidelines in China. The Chinese people’s liberation army general hospital is the largest comprehensive hospital in China, owning more than 4400 beds in all and more than 200 beds in oncology.

The purpose of this study was to survey the off-label and off-NCCN guidelines uses of antineoplastic drugs in the Chinese people’s liberation army general hospital and to understand the actual antineoplastic drug uses in China.

Materials and Methods

All discharged patients in department of oncology were selected from July to December for a randomized week every month in 2011 with the Hospital Information System of the Chinese people’s liberation army general hospital. One thousand one hundred and twenty-two of 1307 (85.84%) patients were submitted to chemotherapy. Except clinical trial drugs, all antitumor drugs were included in this study. According to the latest drug leaflet approved by China's State Food and Drug Administration, the indications (treatment lines, types of cancer and drug combination), drug preparation (solvent and concentration) and route of administration were analyzed. Off-label use was further evaluated with the NCCN guidelines version 1.2011 (including Chinese NCCN version 1.2011) to determine medical orders off the leaflet and NCCN guidelines. The doses of antitumor drugs were not enrolled because they were probably to adjust based on their toxic and specification factors, while some overdoses medical orders would be explained in discussion. Each off-label and off-NCCN guidelines medical order was counted once. Meanwhile, different categorizations on one medical order were needed to count alone. The data were analyzed with the chi square test and statistical software SPSS version 13.0 with test level $\alpha=0.05$. $P$ values less than 0.05 were considered statistically significant.

Results

One thousand one hundred and twenty-two patients were chosen under the defined conditions (Table 1).
Table 1: Characteristics of 1122 patients submitted for chemotherapy

| Characteristic       | No.  | %    |
|---------------------|------|------|
| Sex                 |      |      |
| Female              | 528  | 47.06|
| Male                | 594  | 52.94|
| Age (yr)            |      |      |
| <50                 | 477  | 42.51|
| 50~64               | 518  | 46.17|
| ≥65                 | 127  | 11.32|
| Treatment lines     |      |      |
| Postoperative auxiliary | 371 | 33.06|
| First line          | 510  | 45.45|
| Second line         | 90   | 8.02 |
| Third and multi line| 79   | 7.04 |
| Others $            | 72   | 6.42 |
| Types of cancer     |      |      |
| Lung                | 301  | 26.83|
| Breast              | 204  | 18.18|
| Colorectal          | 187  | 16.67|
| Gastric             | 156  | 13.90|
| Pancreatic          | 49   | 4.37 |
| Head & neck         | 42   | 3.74 |
| Esophageal r        | 36   | 3.21 |
| Neuroendocrine      | 29   | 2.58 |
| Ovarian             | 24   | 2.14 |
| Hepatobiliary       | 19   | 1.69 |
| Others              | 75   | 6.68 |

$ Others include neoadjuvant chemotherapy, first line maintenance, second line maintenance and multi line maintenance.

In 798 of 1122 patients (71.12%), the drugs were used for off-label. In 317 of 1122 patients (28.25%), the drugs were prescribed for off-label and off-NCCN guidelines. In 2591 medical orders for 1122 patients, 1051/2591 (40.56%) medical orders were off-label and off-NCCN guidelines medical orders in 2591 patients, covering such aspects as unapproved indications, unapproved drug concentration and unapproved route of administration. There were four off-label and off-NCCN guidelines medical orders in two aspects. Three hundred and ninety-nine of 445 (89.66%) medical orders were unapproved indication, accounting for the largest percentage. Thirty-eight of 445 (8.54%) medical orders were unapproved drug concentration. For example, concentration of gemcitabine was more than 40 mg/mL, which was forbidden by leaflet; concentration of paclitaxel was lower than 0.3 mg/mL in contrast with concentration of 0.3-1.2 mg/mL demanded by leaflet. In some medical order, the concentration of etoposide, which cannot exceed 0.25 mg/mL according to the leaflet, reached 0.8 mg/mL. Twelve of 445 (2.70%) medical orders involved the unapproved route of administration. For instance, nimotuzumab, pemetrexed and cisplatin were administered for spinal canal injection; gemcitabine and pemetrexed were administered for thoracic injection; rh-endostatin was administered for intraperitoneal injection. All of above route administration were forbidden in the leaflet.

Table 2: Categorization of off-label and off-NCCN guidelines medical orders in 1122 patients

| Categorization                              | No.  | %    |
|---------------------------------------------|------|------|
| Unapproved indication                       | 399  | 89.66|
| Unapproved treatment lines                  | 88   |      |
| Unapproved types of cancer                  | 182  |      |
| Unapproved combination                      | 129  |      |
| Unapproved drug concentration               | 38   | 8.54 |
| Unapproved route of administration          | 12   | 2.7  |
| Unapproved spinal canal injection           | 6    |      |
| Unapproved chest injection                  | 3    |      |
| Unapproved intraperitoneal injection        | 3    |      |

The following data were analyzed by the chi-square test, showing that sex, treatment lines and tumor types were statistically significant in off-label and off-NCCN guidelines uses (P<0.01) (Table 3). Percentage of off-label and off-NCCN guidelines drug uses in male was higher than that in female (21.92% vs. 11.39%, P<0.01). Compared with other lines of treatment, percentage of off-label and off-NCCN guidelines drug uses was the smallest in postoperative adjuvant (P<0.01). Percentage of off-label and off-NCCN guidelines drug uses was highest in three or multi-line treatments (P<0.01). Compared with other tumors, pancreatic cancer possessed higher percentage (38.74%) of off-label and off-NCCN guidelines drug uses (P<0.01). Antineoplastic drugs for off-label and off-NCCN guidelines were ranked according to numbers of medical orders.
Table 3: Off-label and off-NCCN medical orders used on different sex, age, treatment lines and types of cancer

| Categorization        | No. of off-label and off-NCCN medical orders | No. of on-label and on-NCCN medical orders | Total | %     | P     |
|-----------------------|------------------------------------------------|------------------------------------------|-------|-------|-------|
| **Sex**               |                                                 |                                          |       |       |       |
| Female                | 133                                             | 1035                                     | 1168  | 11.39 | <0.01 |
| Male                  | 312                                             | 1111                                     | 1423  | 21.92 |       |
| **Age, yr**           |                                                 |                                          |       |       |       |
| <50                   | 198                                             | 946                                      | 1144  | 17.31 |       |
| 50~64                 | 204                                             | 968                                      | 1172  | 17.41 | >0.05 |
| ≥65                   | 43                                              | 232                                      | 275   | 15.64 |       |
| **Treatment lines**   |                                                 |                                          |       |       |       |
| Third and multi line  | 42                                              | 79                                       | 121   | 34.71 |       |
| Second line           | 31                                              | 125                                      | 156   | 19.87 |       |
| Postoperative auxiliary| 112                                             | 781                                      | 893   | 12.54 | <0.01 |
| First line            | 239                                             | 1018                                     | 1257  | 19.01 |       |
| Others                | 31                                              | 132                                      | 163   | 19.02 |       |
| **Types of cancer**   |                                                 |                                          |       |       |       |
| Colorectal            | 88                                              | 535                                      | 623   | 14.12 |       |
| Lung                  | 74                                              | 445                                      | 519   | 14.26 |       |
| Gastric               | 120                                             | 342                                      | 462   | 25.97 |       |
| Head and Neck         | 30                                              | 87                                       | 117   | 25.64 |       |
| Breast                | 23                                              | 573                                      | 396   | 5.81  |       |
| Pancreatic            | 43                                              | 68                                       | 111   | 38.74 |       |
| Esophageal            | 10                                              | 57                                       | 67    | 14.93 |       |
| Ovarian               | 9                                               | 40                                       | 49    | 18.37 |       |
| Neuroendocrine        | 14                                              | 52                                       | 66    | 21.21 | <0.01 |
| Hepatobiliary         | 4                                               | 32                                       | 36    | 11.11 |       |
| Others                | 30                                              | 115                                      | 145   | 20.69 |       |

The top three drugs in turn were docetaxel, oxaliplatin and capecitabine. Docetaxel was used for unapproved timing, unapproved combination and unapproved types of cancer (Table 4). For instance, DCF chemotherapy was used for first-line treatment of gastric cancer, not for postoperative adjuvant chemotherapy recommended by NCCN guidelines. Docetaxel was in associated with rh-endostatin for treatment of advanced gastric cancer (while docetaxel was not recommended for this combination in NCCN guidelines). Docetaxel was also prescribed to treat the thymus gland tumor and hepatobiliary cancer, not being approved in the leaflet and NCCN. In addition, molecular targeted drugs were ranked the fifth in the top 10 of drugs. Although many clinical studies about molecular targeted drugs were in progress for a relatively short research and development time, the molecular targeted drugs were still widely used due to good effect and little adverse reaction, thus accounting for a higher proportion in for off-label and off-NCCN guidelines cases.

Antitumor drugs such as nimotuzumab, oxaliplatin and rh-endostatin were widely used in all kinds of unapproved cancer treatment (Table 5). The indication of nimotuzumab in association with radiotherapy recommended by the leaflet and NCCN was stage III/IV nasopharyngeal carcinoma when epidermal growth factor receptor (EGFR) expressed positive. Nimotuzumab was widely applied in other types of cancer patients for its action mechanism was similar to cetuximab and its allergic reaction was less than that of cetuximab with complete humanization. Rh-endostatin, a new antiangiogenic drug manufactured by China...
and only for treatment of non-small cell lung cancer (NSCLC) recommend by the leaflet and Chinese NCCN, was also widely used in clinic. Gefitinib was used for treatment of pulmonary metastasis of the colon, mixture of small cell lung cancer (SCLC) and possible adenocarcinoma, unknown primary tumor and pancreatic cancer.

Table 4: The top 10 off-label and off-NCCN guidelines antineoplastic drugs

| Rank | Drug               | No. of medical orders | Classification of the off-label and off-NCCN guidelines (numbers of medical orders) |
|------|--------------------|-----------------------|--------------------------------------------------------------------------------------|
| 1    | Docetaxel          | 78                    | treatment lines 42, combination 30, type of cancer types 6                          |
| 2    | Nimotuzumab        | 55                    | type of cancer 52, route of administration 3                                       |
| 3    | Oxaliplatin        | 54                    | treatment lines 5, combination 23, type of cancer 26                                |
| 4    | Capecitabine       | 48                    | treatment lines 6, combination 35, type of cancer 7                                 |
| 5    | Rh-Endostatin      | 35                    | type of cancer 30, route of administration 2                                        |
| 6    | Erlotinib          | 29                    | treatment lines 10, combination 15, type of cancer 4                                |
| 7    | Gefitinib          | 26                    | treatment lines 6, combination 4, type of cancer 16                                 |
| 8    | Bevacizumab        | 24                    | treatment lines 4, combination 10, type of cancer 10, concentration 23             |
| 9    | Etoposide          | 23                    | concentration 23                                                                   |
| 10   | Pemetrexed         | 21                    | combination 6, type of cancer 12, route of administration 3                         |

In inappropriate treatment lines, docetaxel ranked No. 1. For instance, it was used for postoperative adjuvant chemotherapy of gastric cancer, first line treatment of cervical cancer and SCLC. Erlotinib ranked No. 2 and was used for the postoperative adjuvant, first line without EGFR mutation detection and multi line chemotherapy of NSCLC. Gefitinib ranked No. 3 and was used for the postoperative adjuvant, first line without EGFR mutation detection of NSCLC. Capecitabine was applied for the postoperative adjuvant treatment of stage I and multi line chemotherapy of colorectal cancer. Oxaliplatin was used for the postoperative adjuvant chemotherapy of stage I, stage II A (without risk factors) of colon cancer and multi-line chemotherapy of colorectal cancer (Table 5). The top five drugs with inappropriate combination uses, were capecitabine, docetaxel, oxalipatin, erlotinib and bevacizumab. For instance, combination of capecitabine with docetaxel was used for postoperative adjuvant treatment of gastric cancer (capecitabine, not being registered in leaflet, was recommended by NCCN to combine with oxalipatin by NCCN). Combination cetuximab with oxalipatin and capecitabine, had been deleted from NCCN guidelines since 2010 (Table 5).
## Table 5: Description of off-label and off-NCCN guidelines antineoplastic drugs

| Rank | Drugs         | No. of medical orders |
|------|---------------|-----------------------|
| 1    | Nimotuzumab   | 52                    |
| 2    | Rh-endostatin | 30                    |
| 3    | Oxaliplatin   | 26                    |
| 4    | Gefitinib     | 16                    |
| 5    | Pemetrexed    | 12                    |
| 1    | Docetaxel     | 42                    |
| 2    | Erlotinib     | 10                    |
| 3    | Gefitinib     | 6                     |
| 4    | Capecitabine  | 6                     |
| 5    | Oxaliplatin   | 5                     |
| 1    | Capecitabine  | 35                    |
| 2    | Docetaxel     | 30                    |
| 3    | Oxaliplatin   | 23                    |
| 4    | Erlotinib     | 15                    |
| 5    | Bevacizumab   | 10                    |

### Discussion

In the Chinese people's liberation army general hospital, 1051/2591 (40.56%) medical orders were off-label and 445/2591 (17.17%) medical orders were off-label and off-NCCN. The fact suggests that off-label uses of antineoplastic drugs were common, while most anticancer drug applications followed the evidence of Cochrane in China and therapeutic schedules were relatively standard. The off-label or off-NCCN drug uses in female were less than that in male ($P<0.01$), considering that most women suffered from breast cancer in which therapeutic schedules were more various and standard. Compared with other lines of treatment, three or multi-line treatments possessed the highest percentage of off-label and off-NCCN guidelines cases ($P<0.01$). The clinical trials or best supportive care were recommended in three or multi-line treatment of NCCN, while Chinese doctors kept on empirical treatment with patients’ requests. Compared with other tumors, pancreatic cancer possessed higher percentage (38.74%) of off-label and off-NCCN guidelines cases ($P<0.01$), due to combination of nimotuzumab and other targeted drugs to try high efficacy for poor therapeutic effect in pancreatic cancer (16-18). Although there were no clinical research data to support some off-label and off-NCCN guidelines drugs such as nimotuzumab for brain metastases patients with intrathecal injection, good therapeutic effect was indeed acquired in some patients. Moreover, there was some research for the use of other targeted drugs such as intrathecal rituximab and trastuzumab (19,20). Some NSCLC patients treated with gefitinib or erlotinib were subjected with double doses to overcome drug resistance or achieved a higher cerebrospinal fluid concentration. It occurred when no other good treatment options were available. In addition, the patients were requested to sign the informed consent. The use of high dose gefitinib or erlotinib was also reported in previous reports (21-23). Although some off-label and off-NCCN uses were for the individual treatment, doctors should fully consider adverse drug reactions, contraindications, cautions and increase the drug security monitoring when lacking clinical research data. It has been demonstrated that patients exposed to off-label drug use are at a higher risk of adverse drug effects (24,25). Uncorrected drug concentration should be avoided for drug risk in some off-label drug uses. Some important limitations were presented in this study, such as the scarce number of patients evaluated, which contrasts with the large variability induced by the variety of the type of neoplasm, of chemotherapeutic schemes, of antineoplastic
drugs used, etc. Meanwhile, the doses of antitumor drug were not enrolled due to difficult evaluation. Precisely, because some of the different identified categories are not mutually exclusive and the choice of prevalence criteria to classify each one of them possesses a component of arbitrariness. In addition, analysis data was only from one hospital and only from department of oncology. All these limitations suggest that further multi-center research was needed in the future.

Conclusion

Off-label uses of antineoplastic drugs are generally common in China hospitals based on NCCN guidelines. The fact suggests that anti-tumor treatment was relatively standard in China.

Ethical considerations

Ethical issues (Including plagiarism, Informed Consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc) have been completely observed by the authors.

Acknowledgment

The authors thank Xiutang CAO from Dept of statistics, Chinese PLA General Hospital, for his help in statistical method of this study. The authors declare that there is no conflict of interest.

References

1. American Academy of Pediatrics (2002). Uses of drugs not described in the package insert (off-label uses). Pediatrics, 110(1):181-183.
2. American Society of Clinical Oncology (2006). Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol, 24(19):3206-3208.
3. Soares M(2005). “Off-label” indications for oncology drug use and drug compendia: History and current status. J Oncol Pract, 1(3):102.
4. Conroy S, Newman C, Gudka S(2003). Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol, 14(1):42-47.
5. Leveque D, Michallat A C, Schaller C, Ranca M(2005). Off label drug use in adult patients treated by anticancer chemotherapy. Bulletin du cancer, 92(5):498-500.
6. Poole SG., Dooley MJ. Off-label prescribing in oncology(2004). Supportive Care Cancer, 12(5):302-305.
7. Laetz T, Silberman G(1991). Reimbursement policies constrain the practice of oncology. JAMA, 266(21):2996-2999.
8. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Freeman J; Goodwin JS(2006). Impact of a scientific presentation on community treatment pattern for primary breast cancer. J Natl Cancer Inst, 98(6):382-388.
9. Redmond K(2004). The US and European regulatory systems: a comparison. J Ambulatory Care Manage, 27(2):105-114.
10. Leveque D(2008). Off-label use of anticancer drugs. Lanzet Oncol, 9 (11): 1102-1107.
11. Casali PG(2007). The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol, 18(12):1923-1925.
12. ASCO supports government report(1991) Off-label drugs: reimbursement policies constrain physicians in choice of cancer therapies. Oncology (Williston Park), 5 (10): 29-30, 33.
13. Rolia F, Enzo Ballatori, Roberto Labianca, Filippo De Braud, Karen Borgonovo, Olga Martelli, et al(2009). Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. Tumori, 95(6):647-651.
14. Mellor JD, Van Koevorden P, Yip SW, Thakerar A, Kirs SW, Michael M(2012). Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme. Intern Med J,42(11): 1224-1229.
15. Gota V, Patial P(2011). Off-label use of anti-cancer drugs in India: to be or not to be! J Cancer Res Ther, 7(1):35-39.
16. Cinar P, Tempero MA(2012). Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J., 18(6):653-664.
17. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, et al(2012). Phase II study of nimotuzumab, a humanized mono-
clonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. *Invest New Drugs*, 30(3):1138-1143.

18. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, et al. (2010). Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. *Int J Clin Pharmacol Ther*, 48(7):473-485.

19. Maximiano Alonso C, Sánchez Ruiz AC, Cantos Sánchez de Ibargüen B, Méndez García M, Ronco IS, Provencio Pulla M (2010). Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. *Clin Transl Oncol*, 12(10):701.

20. Perissinotti AJ, Reeves DJ (2010). Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. *Ann Pharmacother*, 44(10):1633-1640.

21. Baldini E, Prochilo T, Boldrini L, Melfi F, Fontanini G (2008). Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation. *Mol Med Rep*, 1(1):41-43.

22. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB (2010). High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. *J Neurooncol*, 99(2):283–286.

23. Togashi Y, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, et al. (2011). Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. *Cancer Chemother Pharmacol*, 68(4):1089-1092.

24. Cohen JS (2001). Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference. *Arch Intern Med*, 161(6):880-885.

25. Horen B, Montastruc JL, Lapeyre-Mestre M (2002). Adverse drug reactions and off-label drug use in paediatric outpatients. *Brit J Clin Pharmac*, 54(6):665-670.

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
کارگاه‌های آموزشی مرکز اطلاعات علمی جهاد دانشگاهی

کارگاه آنلاین اصول تنظیم قراردادها

کارگاه آنلاین بروزهای نویسی

کارگاه آنلاین کاربرد نرم افزار SPSS در پژوهش